© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Quantum BioPharma Ltd. (QNTM) stock surged +52.58%, trading at $4.73 on NASDAQ, up from the previous close of $3.10. The stock opened at $3.05, fluctuating between $3.01 and $4.82 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 23, 2026 | 2.21 | 3.35 | 2.18 | 3.10 | 1.36M |
| Mar 20, 2026 | 2.32 | 2.38 | 2.20 | 2.24 | 72.77K |
| Mar 19, 2026 | 2.31 | 2.40 | 2.31 | 2.36 | 40.73K |
| Mar 18, 2026 | 2.37 | 2.46 | 2.33 | 2.40 | 71.75K |
| Mar 17, 2026 | 2.41 | 2.42 | 2.28 | 2.40 | 74.57K |
| Mar 16, 2026 | 2.47 | 2.48 | 2.32 | 2.36 | 173.75K |
| Mar 13, 2026 | 2.47 | 2.61 | 2.35 | 2.48 | 263.37K |
| Mar 12, 2026 | 2.23 | 3.20 | 2.11 | 2.56 | 3.14M |
| Mar 11, 2026 | 2.94 | 3.05 | 2.07 | 2.10 | 814.49K |
| Mar 10, 2026 | 3.36 | 3.51 | 2.80 | 2.80 | 338.07K |
| Mar 09, 2026 | 3.40 | 3.48 | 3.32 | 3.36 | 37.12K |
| Mar 06, 2026 | 3.53 | 3.75 | 3.45 | 3.50 | 53.66K |
| Mar 03, 2026 | 3.60 | 3.80 | 3.57 | 3.75 | 29.81K |
| Mar 02, 2026 | 3.50 | 3.65 | 3.41 | 3.60 | 45.49K |
| Feb 27, 2026 | 3.55 | 3.76 | 3.51 | 3.55 | 31.21K |
| Feb 26, 2026 | 3.77 | 3.83 | 3.55 | 3.58 | 30.03K |
| Feb 25, 2026 | 3.81 | 3.86 | 3.73 | 3.79 | 24.2K |
| Feb 24, 2026 | 3.53 | 3.84 | 3.53 | 3.81 | 22.87K |
| Feb 23, 2026 | 3.65 | 3.73 | 3.52 | 3.54 | 50.56K |
| Feb 20, 2026 | 3.72 | 4.00 | 3.63 | 3.69 | 34.63K |
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
| Employees | 0 |
| Beta | 0.6 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |